Portland, Oregon 97239


The primary focus of this five-year study will be to optimize the melatonin dosing regimen for synchronizing the body clocks of blind children to the 24-hour day.

Study summary:

We intend to study as many as 26 blind children through up to three melatonin treatment regimens, all of which involve a dose step-down in which the melatonin dose will be reduced gradually to find the lowest effective dose. The 3 treatment plans differ only in the start dose. Successfully treated subjects (of one treatment plan) will enter a one-year intensive assessment of the safety and efficacy of melatonin treatment in which the subject will take the same dose for one year and complete biweekly assessments of efficacy and side-effects. The final phase of the study involves a placebo discontinuation, in which the subject's circadian rhythm will be returned to the baseline rhythm (this may take up to 6 months for some subjects).


Inclusion Criteria: - Children and adults 5 to 20 years old - Blindness for at least one year, verified by an ophthalmologic exam - Ability to comply with the requirements of the experimental protocol - And no clinically significant abnormalities (other than blindness) on a general physical examination. - Subjects must be competent to sign informed consent if age 18 or older. Parents and subjects will be interviewed together and, when appropriate (for example, subject is age 18 or older), separately as well. Exclusion Criteria: - Abnormal heart, liver or kidney function; intractable seizure disorders - Significant laboratory abnormalities on CBC, Comprehensive Metabolic set, or UA (dip stick method) - Pregnancy; sexual activity in post-pubertal females not using a recognized and valid contraceptive method - A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual ; OR - External demands that limit the ability to maintain a regular schedule, e.g. night shift work.



Primary Contact:

Principal Investigator
Alfred J Lewy, MD, PhD
Oregon Health and Science University

Amber Laurie
Phone: 1-866-424-6060
Email: sleeplab@ohsu.edu

Backup Contact:

Email: lewy@ohsu.edu
Alfred J Lewy, MD, PhD
Phone: 503-494-7746

Location Contact:

Portland, Oregon 97239
United States

Amber Laurie, B.A.
Phone: 866-424-6060
Email: sleeplab@ohsu.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.